Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis

Psoriasis Clinical Trial

Official title:

A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00716144
• Other study ID #: BT0720-201-INT
• Status: Completed
• Phase: Phase 2
• First received: July 15, 2008
• Last updated: June 28, 2017
• Start date: June 1, 2006
• Est. completion date: May 1, 2007

Study information

• Verified date: May 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and efficacy of R115866 will be evaluated during the treatment period and the 8-week post treatment follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 176
• Est. completion date: May 1, 2007
• Est. primary completion date: May 1, 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Plaque Psoriasis with PASI greater than or equal to 10

• Male or a female who was NOT of childbearing potential (i.e., post- menopausal for greater than 12 months or had a complete hysterectomy);

Exclusion Criteria:

• Spontaneously improving or rapidly deteriorating plaque psoriasis

• Guttate, pustular, erythrodermic, or other non-plaque form of psoriasis

• Subject was under treatment for a heart disorder or had a history of cardiovascular disease (excluding effectively controlled hypertension)

• Any acute psychiatric condition, including an increased risk for suicide attempt, based on medical and psychiatric history

• Previous use of a psoriasis vaccine or had participated in an investigational study of a psoriasis vaccine

• Previous use of systemic immunomodulatory therapy known to affect psoriasis and to typically decrease immune cell populations

• Previous use of any systemic immunomodulatory therapy known to affect psoriasis and NOT typically to decrease immune cell populations

• Previous use of any photo-therapy (including laser), photo-chemotherapy, or systemic psoriasis therapy (such as systemic corticosteroids, methotrexate, retinoids, or cyclosporine) within the previous four weeks

• Pregnant or a nursing mother

• Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic pancreatitis, osteoporosis, cancer (except non-melanoma skin cancer), a positive test for human immunodeficiency virus (HIV), a history indicating adrenal cortex dysfunction

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• Talarozole
Oral Capsule Once Daily

Locations

Country	Name	City	State
Germany	GSK Investigational Site	Augsburg
Germany	GSK Investigational Site	Berlin
Germany	GSK Investigational Site	Dresden
Germany	GSK Investigational Site	Frankfurt
Germany	GSK Investigational Site	Hamburg
Germany	GSK Investigational Site	Salzwedel
Ireland	GSK Investigational Site	Cork
Netherlands	GSK Investigational Site	Maastricht
Netherlands	GSK Investigational Site	Nijmegen
Russian Federation	GSK Investigational Site	Korolev
Russian Federation	GSK Investigational Site	Lipetsk
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	Novgorod
Russian Federation	GSK Investigational Site	Smolensk
Russian Federation	GSK Investigational Site	St. Petersburg
Russian Federation	GSK Investigational Site	Yaroslavl
United Kingdom	GSK Investigational Site	Aberdeen
United Kingdom	GSK Investigational Site	Amersham
United Kingdom	GSK Investigational Site	Coventry
United Kingdom	GSK Investigational Site	Glasgow
United Kingdom	GSK Investigational Site	Manchester
United Kingdom	GSK Investigational Site	Norwich

Sponsors (2)

Lead Sponsor	Collaborator
Stiefel, a GSK Company	GlaxoSmithKline

Countries where clinical trial is conducted

Germany,  Ireland,  Netherlands,  Russian Federation,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psoriasis Area Severity Index (PASI)75 Success at Visit 6	PASI75 success at Visit 6 was defined as number of participants who achieved at least 75% reduction in PASI scores at Visit 6 compared to Visit 2 (Baseline). The PASI score was determined through evaluation of body surface area (BSA) covered by plaque psoriasis in four regions (head/neck, upper extremities, trunk and lower extremities). This assessment included a combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale that ranged as 0 (0% involvement), 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89% and 6 = 90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0 = No evidence of sign, 1 = slight evidence of sign, 2 = moderate evidence of sign, 3 = marked evidence of sign and 4 = very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same four regions. PASI score ranged from 0 to 72 in 0.1-unit intervals; higher scores indicating worse psoriasis.	Week 12 (Visit 6)
Secondary	PASI50 Success (the Reduction in PASI Score at Each Visit of at Least 50 Percent Relative to Visit 2) at Each Post Baseline Visit	PASI50 success was defined as number of participants who achieved at least 50% reduction in PASI scores at each post baseline visit (Visit 3 to 8) compared to Visit 2 (Baseline). The PASI score was determined through evaluation of BSA covered by plaque psoriasis in four regions (head/neck, upper extremities, trunk and lower extremities). This assessment included a combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale that ranged as 0 (0% involvement), 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89% and 6 = 90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0 = No evidence of sign, 1 = slight evidence of sign, 2 = moderate evidence of sign, 3 = marked evidence of sign and 4 = very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same four regions. PASI score ranged from 0 to 72 in 0.1-unit intervals; higher scores indicating worse psoriasis.	Week 1 to Week 20 (Visit 3 to Visit 8)
Secondary	Investigator's Global Assessment (IGA) at Each Post Baseline Visit	The IGA was used to assess the overall severity of a participant's plaque psoriasis at a particular time point and the evaluation took into consideration the three individual characteristics of plaque psoriasis (scaling, plaque elevation, and erythema). The IGA was recorded using a scale that ranged from 0 (clear), 1 = almost clear, 2 = mild, 3 = moderate to 4 (severe) in whole-unit increments; higher scores indicating worse psoriasis. Investigators did not refer to previous evaluations when conducting the IGA assessment. At every study visit, the investigator evaluated each participant's plaque psoriasis and recorded the one integer grade that best described the average, overall severity of the condition. Investigators were trained not to refer to previous assessments of the IGA, and not to base the IGA scores on any component of the PASI. Individual body regions were not assessed (as in the PASI), but rather a global evaluation for each participant at each visit was determined.	Week 1 to Week 20 (Visit 3 to Visit 8)
Secondary	PASI75 at Each Post Baseline Visit Except Visit 6	PASI75 success was defined as number of participants who achieved at least 75% reduction in PASI scores at each post baseline visit (Visit 3 to Visit 8) except Visit 6. The PASI score was determined through evaluation of BSA covered by plaque psoriasis in four regions (head/neck, upper extremities, trunk and lower extremities). This assessment included a combination of both degree of involvement (assessed as per the % of affected body area using a 7-point scale that ranged as 0 (0% involvement), 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89% and 6 = 90-100%) and severity (evaluated individually using a 5-point scale that ranged as 0 = No evidence of sign, 1 = slight evidence of sign, 2 = moderate evidence of sign, 3 = marked evidence of sign and 4 = very marked, most severe evidence of sign) of erythema, induration and desquamation in each of the same four regions. PASI score ranged from 0 to 72 in 0.1-unit intervals; higher scores indicating worse psoriasis.	Week 1 to Week 20 (Visit 3 to Visit 8) except Week 12 (Visit 6)